)
)
)
Resolution Therapeutics
March 02, 2026
Ballroom II C
Type: Company Presentation
Focus Area:
Gene/Cell Therapy
Resolution Therapeutics is a clinical stage pioneer in Regenerative Macrophage Therapies (RMT) for Inflammatory and Fibrotic Diseases. CLINICAL PROGRAM / HIGH UNMET NEED - EMERALD/OPAL (P1/2) for End Stage Liver Disease (ESLD), which affects >500k people in the US with liver transplantation as the only option, leaving over 90% of patients with no alternative. TRANSFORMATIVE TREATMENT - Engineered macrophages with enhanced anti-inflammatory and anti-fibrotic efficacy, optimised by payload ROBUST SCIENCE & CLINICAL EVIDENCE - Two clinical Proof of Concept studies demonstrating safety and efficacy in patients with cirrhosis; robust biomarker package FOCUSED PIPELINE - Efficacy demonstrated in lung fibrosis and GvHD with platform expansion into In Vivo modality
Year Founded:
2020
Lead Product in Development:
EMERALD/OPAL - RTX001 for decompensated cirrhosis
Speakers
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
